Free tool
FAERS Monitor: Unasyn
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050608 or its brand name (Unasyn, Ampicillin Sodium, Sulbactam Sodium). Reports on generic versions are filed under their own applications.
Reports
1,708
Serious
1,594
93% of reports
Hospitalization
869
Death reported
337
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- pneumonia146
- pyrexia129
- dyspnoea88
- diarrhoea80
- pain77
- rash75
- drug ineffective65
- vomiting64
- sepsis63
- nausea61
- hepatic function abnormal59
- hypotension59
- anaemia54
- anxiety54
- interstitial lung disease52
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 104 |
| 2005 | 105 |
| 2006 | 95 |
| 2007 | 100 |
| 2008 | 90 |
| 2009 | 56 |
| 2010 | 122 |
| 2011 | 139 |
| 2012 | 106 |
| 2013 | 51 |
| 2014 | 65 |
| 2015 | 79 |
| 2016 | 91 |
| 2017 | 66 |
| 2018 | 59 |
| 2019 | 50 |
| 2020 | 44 |
| 2021 | 58 |
| 2022 | 40 |
| 2023 | 68 |
| 2024 | 60 |
| 2025 | 31 |
| 2026 | 29 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,451 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hepatic function abnormalSignal | 59 | 19.5 | 15.2 | 1,017 |
| interstitial lung diseaseSignal | 52 | 13.2 | 10.1 | 577 |
| sepsisSignal | 63 | 7.0 | 5.5 | 317 |
| pneumoniaSignal | 146 | 5.6 | 4.8 | 549 |
| pyrexiaSignal | 129 | 4.6 | 3.9 | 365 |
| hypotensionSignal | 59 | 3.6 | 2.8 | 110 |
| anaemiaSignal | 54 | 3.5 | 2.7 | 94 |
| anxietySignal | 54 | 2.3 | 1.8 | 41 |
| rashSignal | 75 | 2.1 | 1.7 | 44 |
| dyspnoea | 88 | 1.9 | 1.6 | 39 |
| vomiting | 64 | 1.7 | 1.3 | 17 |
| pain | 77 | 1.5 | 1.2 | 15 |
| diarrhoea | 80 | 1.5 | 1.2 | 14 |
| nausea | 61 | 0.9 | 0.7 | 0 |
| drug ineffective | 65 | 0.6 | 0.5 | 17 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.